Ambry Genetics, a subsidiary of Tempus AI Inc., has announced a significant validation of its CARE Program® for hereditary cancer risk assessment. A peer-reviewed study published in the Journal of the National Comprehensive Cancer Network confirms the program's accuracy in interpreting NCCN Clinical Practice Guidelines with 99.5% accuracy. This reinforces CARE's role as an effective digital risk assessment tool, aiding in the identification of patients who may benefit from genetic testing and personalized care. The program integrates with electronic health records and collects comprehensive medical and family histories directly from patients, facilitating proactive and personalized healthcare. This development supports Ambry Genetics' mission to expand access to genetic services and improve patient outcomes.